ImmunityBio (IBRX) Cash from Financing Activities (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Cash from Financing Activities data on file, last reported at $223.9 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 22903.05% year-over-year to $223.9 million in Q1 2026; TTM through Mar 2026 was $625.1 million, a 131.17% increase from a year earlier, with the FY2025 full-year figure at $400.2 million, up 42.12% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $223.9 million, up from $54.9 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for IBRX reached as high as $237.5 million in Q3 2023 and fell as low as -$982000.0 in Q1 2025.
• Historically, Cash from Financing Activities has averaged $99.9 million across 5 years, with a median of $106.9 million in 2024.
• Across the five-year window, Cash from Financing Activities soared 289513.33% in 2023 and plunged 109.6% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $109.9 million in 2022, then jumped by 82.41% to $200.5 million in 2023, then slumped by 46.68% to $106.9 million in 2024, then sank by 48.66% to $54.9 million in 2025, then soared by 307.92% to $223.9 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $223.9 million in Q1 2026, $54.9 million in Q4 2025, and $173.5 million in Q3 2025.